HC Wainwright Analysts Cut Earnings Estimates for Indaptus Therapeutics, Inc. (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Equities researchers at HC Wainwright lowered their Q1 2024 earnings per share estimates for shares of Indaptus Therapeutics in a research report issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.57) per share for the quarter, down from their prior estimate of ($0.44). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS and FY2024 earnings at ($1.83) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07.

Indaptus Therapeutics Trading Down 4.7 %

Shares of NASDAQ:INDP opened at $2.66 on Wednesday. The stock has a 50 day moving average of $2.13 and a 200 day moving average of $2.10. The company has a market cap of $22.72 million, a PE ratio of -1.45 and a beta of 1.28. Indaptus Therapeutics has a 12-month low of $1.56 and a 12-month high of $4.08.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Indaptus Therapeutics by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after purchasing an additional 5,517 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Indaptus Therapeutics in the 2nd quarter worth approximately $51,000. State Street Corp purchased a new position in Indaptus Therapeutics in the 1st quarter worth approximately $78,000. Citadel Advisors LLC purchased a new position in Indaptus Therapeutics in the 4th quarter worth approximately $29,000. Finally, Northern Trust Corp purchased a new position in Indaptus Therapeutics in the 1st quarter worth approximately $41,000. 7.06% of the stock is owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.